A new international Phase III clinical trial has found that an investigational once-weekly HIV treatment was as effective as a standard once-daily regimen, offering hope for a more convenient option for people living with HIV.
Researchers reported that the once-weekly oral combination successfully maintained viral suppression while demonstrating safety and efficacy comparable to Biktarvy, one of the most commonly prescribed once-daily HIV treatments. The findings suggest that reducing the number of doses from seven pills a week to one could improve treatment adherence for some patients if the therapy ultimately receives regulatory approval.
Although the therapy remains investigational, infectious disease specialists say the results represent another important step toward expanding treatment options for HIV, a chronic viral infection that now can often be managed successfully with lifelong antiretroviral therapy.
Once-weekly regimen matched Biktarvy in an international study
The Phase III study evaluated a once-weekly oral regimen consisting of islatravir and lenacapavir and compared it with Biktarvy, a once-daily fixed-dose combination containing bictegravir, emtricitabine, and tenofovir alafenamide. Researchers found that the once-weekly treatment was noninferior to the daily regimen, meaning it maintained viral suppression at rates comparable to Biktarvy while meeting the trial's primary efficacy endpoint. According to the published findings, the safety profile of the weekly regimen was also generally comparable to that of the standard daily therapy.
The global trial enrolled adults living with HIV whose virus was already well controlled on antiretroviral therapy before entering the study. Participants represented multiple countries and diverse demographic backgrounds, allowing investigators to evaluate the regimen across a broad population. Researchers noted that simplifying treatment to a once-weekly schedule could help some patients who find it challenging to take medication every day, though they emphasized that additional regulatory review will be required before the therapy becomes widely available.
Understanding HIV and How a Once-Weekly Pill Could Change Treatment
According to the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), human immunodeficiency virus (HIV) attacks the body's immune system by targeting CD4 T lymphocytes, making it harder to fight infections and certain cancers if left untreated.
HIV spreads through contact with certain body fluids, including blood, semen, vaginal fluids, rectal fluids, and breast milk, from a person with HIV who has a detectable viral load. It is not spread through casual contact such as hugging, shaking hands, sharing food, or insect bites.
Some people experience flu-like symptoms within two to four weeks after infection, while others may have no symptoms for years. Without treatment, HIV can progressively weaken the immune system and eventually lead to acquired immunodeficiency syndrome (AIDS), the most advanced stage of HIV infection.
Diagnosis is made through laboratory testing that detects HIV antibodies, antigens, or viral genetic material. Risk factors include having unprotected sex, sharing needles or syringes, and other exposures to infected body fluids. Early diagnosis and prompt treatment greatly improve long-term health outcomes and reduce the risk of transmission.
The Current HIV Treatment Method: How the Experimental Pill Becomes of Use
Current HIV treatment relies on combinations of antiretroviral therapy (ART) that suppress viral replication rather than cure the infection. Most people take medication every day to maintain an undetectable viral load, which both protects their immune system and prevents sexual transmission of HIV when viral suppression is consistently maintained.
If approved by regulators, the once-weekly regimen evaluated in this study could provide an alternative for appropriate patients by reducing dosing frequency while maintaining the same goal of durable viral suppression. Researchers emphasized, however, that the investigational pill is intended to treat HIV, not prevent infection or cure the disease, and that further regulatory review is needed before it becomes available for routine clinical use.
A Hopeful Future For Those Seeking Treatment
The study highlights how advances in HIV treatment continue to focus not only on effectiveness but also on improving quality of life for people living with the virus. Simplifying medication schedules may help some patients maintain long-term adherence, an essential factor in preventing viral rebound, preserving immune function, and reducing the likelihood of drug resistance.
The findings also underscore the remarkable progress made in HIV care over the past several decades. While HIV remains a lifelong condition without a cure, modern antiretroviral therapy enables many people to live long, healthy lives. Continued research into longer-acting medications, including weekly pills and long-acting injectable therapies, may further expand treatment options, allowing healthcare providers to tailor care to individual patients while supporting sustained immune system health and effective viral suppression.
